TOP2B and heart failure: Doxorubicin (Dox), a clinically used anthracycline with broad‐spectrum antitumor activity, is associated with severe cardiotoxicity, that leads to acute or late‐onset heart failure.[1] It has been demonstrated that doxorubicin can target topoisomerase IIβ to increase reactive oxygen species, drive mitochondrial dysfunction, and result in myocardial loss and heart failure.[2] Clinically, doxorubicin‐induced cardiomyopathy (DIC) is dose‐cumulative dependent and can occur long after treatment.